An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
Read time: 1 mins
Last updated:21st Sep 2011
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age. Approximately half of the subjects will be recruited during the first study year and will be followed during approximately 6-8 months for efficacy and safety. The recruitment of an independent cohort during the second study year will be based on the results of the first year.
|Study start date||2011-09-21|